GRIM-19 disrupts E6/E6AP complex to rescue p53 and induce apoptosis in cervical cancers

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Zhou, Ying ^a   Wei, Ying ^a   Zhu, Jing ^a   Wang, Qingyuan ^a   Bao, Liang ^b   Ma, Yang ^b   Chen, Yu ^a   Feng, Dingqing ^a   Zhang, Aijin ^b   Sun, Jie ^b   Nallar, Shreeram C ^c   Shen, Keng ^d   Kalvakolanu, Dhananjaya V ^c   Xiao, Weihua ^b   Ling, Bin ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

E6 ASSOCIATED PROTEIN; ONCOPROTEIN; PROTEIN E6; PROTEIN GRIM 19; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; GRIM19 PROTEIN, HUMAN; OXIDOREDUCTASE; UBE3A PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING COMPETITION; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSMISSION ELECTRON MICROSCOPY; UBIQUITINATION; UTERINE CERVIX CANCER; ANIMAL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; DOWN REGULATION; METABOLISM; PATHOLOGY; PROTEIN STABILITY; TUMOR CELL LINE; ULTRASTRUCTURE; UTERINE CERVIX TUMOR;

HUMAN PAPILLOMAVIRUS;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; G0 PHASE; G1 PHASE; HUMANS; MICE; NADH, NADPH OXIDOREDUCTASES; ONCOGENE PROTEINS, VIRAL; PROTEIN BINDING; PROTEIN STABILITY; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; UTERINE CERVICAL NEOPLASMS;

EID: 79960186102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022065     Document Type: Article

References (60)

1. Moody CA, Laimins LA, (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10: 550-560.
2. Marur S, D'Souza G, Westra WH, Forastiere AA, (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11: 781-789.
3. Syrjanen KJ, (2002) HPV infections and lung cancer. J Clin Pathol 55: 885-891.
4. El-Mofty SK, (2007) Human papillomavirus (HPV) related carcinomas of the upper aerodigestive tract. Head Neck Pathol 1: 181-185.
5. Moscicki AB, Schiffman M, Kjaer S, Villa LL, (2006) Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 24 (Suppl 3): S3/42-51.
6. Beaudenon S, Huibregtse JM, (2008) HPV E6, E6AP and cervical cancer. BMC Biochem 9 (Suppl 1): S4.
7. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM, (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
8. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM, (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
9. Kuballa P, Matentzoglu K, Scheffner M, (2007) The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins. J Biol Chem 282: 65-71.
10. Gewin L, Myers H, Kiyono T, Galloway DA, (2004) Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 18: 2269-2282.
11. Zhao CY, Szekely L, Bao W, Selivanova G, (2010) Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res 70: 3372-3381.
12. Wang H, Mo P, Ren S, Yan C, (2010) Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. J Biol Chem 285: 13201-13210.
13. Sehr P, Pawlita M, Lewis J, (2007) Evaluation of different glutathione S-transferase-tagged protein captures for screening E6/E6AP interaction inhibitors using AlphaScreen. J Biomol Screen 12: 560-567.
14. Baleja JD, Cherry JJ, Liu Z, Gao H, Nicklaus MC, et al. (2006) Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res 72: 49-59.
15. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV, (2000) Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem 275: 33416-33426.
16. Lufei C, Ma J, Huang G, Zhang T, Novotny-Diermayr V, et al. (2003) GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 22: 1325-1335.
17. Zhang J, Yang J, Roy SK, Tininini S, Hu J, et al. (2003) The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci U S A 100: 9342-9347.
18. Alchanati I, Nallar SC, Sun P, Gao L, Hu J, et al. (2006) A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 25: 7138-7147.
19. Zhang L, Gao L, Li Y, Lin G, Shao Y, et al. (2008) Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin Cancer Res 14: 559-568.
20. Zhou Y, Li M, Wei Y, Feng D, Peng C, et al. (2009) Down-regulation of GRIM-19 expression is associated with hyperactivation of STAT3-induced gene expression and tumor growth in human cervical cancers. J Interferon Cytokine Res 29: 695-703.
21. Sun P, Nallar SC, Kalakonda S, Lindner DJ, Martin SS, et al. (2009) GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring. Oncogene 28: 1339-1347.
22. Sun P, Nallar SC, Raha A, Kalakonda S, Velalar CN, et al. (2010) GRIM-19 and p16(INK4a) synergistically regulate cell cycle progression and E2F1-responsive gene expression. J Biol Chem 285: 27545-27552.
23. Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, et al. (2003) The role of TP53 in Cervical carcinogenesis. Hum Mutat 21: 307-312.
24. Scheffner M, (1998) Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 78: 129-139.
25. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M, (2001) Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci U S A 98: 1218-1223.
26. Seo T, Lee D, Shim YS, Angell JE, Chidambaram NV, et al. (2002) Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death. J Virol 76: 8797-8807.
27. Yamamoto Y, Huibregtse JM, Howley PM, (1997) The human E6-AP gene (UBE3A) encodes three potential protein isoforms generated by differential splicing. Genomics 41: 263-266.
28. Talis AL, Huibregtse JM, Howley PM, (1998) The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 273: 6439-6445.
29. Ramamoorthy S, Nawaz Z, (2008) E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors. Nucl Recept Signal 6: e006.
30. Masson M, Hindelang C, Sibler AP, Schwalbach G, Trave G, et al. (2003) Preferential nuclear localization of the human papillomavirus type 16 E6 oncoprotein in cervical carcinoma cells. J Gen Virol 84: 2099-2104.
31. Kelley ML, Keiger KE, Lee CJ, Huibregtse JM, (2005) The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol 79: 3737-3747.
32. Zhang HM, Yuan J, Cheung P, Chau D, Wong BW, et al. (2005) Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression. Mol Cell Biol 25: 6247-6258.
33. Yang YC, Hsu YT, Wu CC, Chen HT, Chang MS, (2006) Silencing of astrin induces the p53-dependent apoptosis by suppression of HPV18 E6 expression and sensitizes cells to paclitaxel treatment in HeLa cells. Biochem Biophys Res Commun 343: 428-434.
34. Nuber U, Schwarz SE, Scheffner M, (1998) The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. Eur J Biochem 254: 643-649.
35. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
36. Castellsague X, (2008) Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 110: S4-7.
37. Hou SY, Wu SY, Chiang CM, (2002) Transcriptional activity among high and low risk human papillomavirus E2 proteins correlates with E2 DNA binding. J Biol Chem 277: 45619-45629.
38. Hegde RS, (2002) The papillomavirus E2 proteins: structure, function, and biology. Annu Rev Biophys Biomol Struct 31: 343-360.
39. Blachon S, Demeret C, (2003) The regulatory E2 proteins of human genital papillomaviruses are pro-apoptotic. Biochimie 85: 813-819.
40. Lee D, Kwon JH, Kim EH, Kim ES, Choi KY, (2010) HMGB2 stabilizes p53 by interfering with E6/E6AP-mediated p53 degradation in human papillomavirus-positive HeLa cells. Cancer Lett 292: 125-132.
41. Shai A, Pitot HC, Lambert PF, (2010) E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res 70: 5064-5073.
42. Niu G, Wright KL, Ma Y, Wright GM, Huang M, et al. (2005) Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25: 7432-7440.
43. Lin J, Tang H, Jin X, Jia G, Hsieh JT, (2002) p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene 21: 3082-3088.
44. Lee TL, Yeh J, Friedman J, Yan B, Yang X, et al. (2008) A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 122: 1987-1998.
45. Murph MM, Hurst-Kennedy J, Newton V, Brindley DN, Radhakrishna H, (2007) Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells. Mol Cancer Res 5: 1201-1211.
46. Ma X, Kalakonda S, Srinivasula SM, Reddy SP, Platanias LC, et al. (2007) GRIM-19 associates with the serine protease HtrA2 for promoting cell death. Oncogene 26: 4842-4849.
47. Yeo WM, Isegawa Y, Chow VT, (2008) The U95 protein of human herpesvirus 6B interacts with human GRIM-19: silencing of U95 expression reduces viral load and abrogates loss of mitochondrial membrane potential. J Virol 82: 1011-1020.
48. Narisawa-Saito M, Kiyono T, (2007) Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci 98: 1505-1511.
49. Song S, Pitot HC, Lambert PF, (1999) The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol 73: 5887-5893.
50. Nguyen M, Song S, Liem A, Androphy E, Liu Y, et al. (2002) A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo. J Virol 76: 13039-13048.
51. Oda H, Kumar S, Howley PM, (1999) Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc Natl Acad Sci U S A 96: 9557-9562.
52. Zaaroor-Regev D, de Bie P, Scheffner M, Noy T, Shemer R, et al. (2010) Regulation of the polycomb protein Ring1B by self-ubiquitination or by E6-AP may have implications to the pathogenesis of Angelman syndrome. Proc Natl Acad Sci U S A 107: 6788-6793.
53. Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, et al. (2009) E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ 16: 1156-1166.
54. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, et al. (1998) Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 21: 799-811.
55. Fang P, Lev-Lehman E, Tsai TF, Matsuura T, Benton CS, et al. (1999) The spectrum of mutations in UBE3A causing Angelman syndrome. Hum Mol Genet 8: 129-135.
56. Kishino T, Lalande M, Wagstaff J, (1997) UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 15: 70-73.
57. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW, (1999) Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci U S A 96: 1858-1862.
58. Mou HZ, Xu SH, Zhang YY, (1994) [The establishment of human ovarian carcinoma cell line HO-8910 and its characteristics]. Zhonghua Fu Chan Ke Za Zhi 29: 162-164, 191.
59. Sun G, Zhou J, Yin A, Ding Y, Zhong M, (2008) Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line. Int J Oncol 32: 1065-1071.
60. Hodge DR, Xiao W, Wang LH, Li D, Farrar WL, (2004) Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells. Cancer Biol Ther 3: 188-194.